Effects on cardiac, renal, and vascular endothelial markers after switching to topiroxostat from febuxostat treatment among IGT patients

Trial Profile

Effects on cardiac, renal, and vascular endothelial markers after switching to topiroxostat from febuxostat treatment among IGT patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Topiroxostat (Primary)
  • Indications Hyperuricaemia
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 01 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top